Thelansis

Bardet-Biedl Syndrome (BBS) Market Outlook Thelansis’s “Bardet-Biedl Syndrome (BBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bardet-Biedl Syndrome (BBS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

Bardet-Biedl Syndrome (BBS) Market Outlook Thelansis’s “Bardet-Biedl Syndrome (BBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bardet-Biedl Syndrome (BBS)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Bardet-Biedl Syndrome (BBS) Overview Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive ciliopathy, primarily affecting children born from consanguineous marriages. It presents with diverse manifestations, including rod-cone dystrophy, postaxial polydactyly, obesity, learning disabilities, and genital and renal abnormalities. Visual prognosis is typically poor, with legal blindness occurring around age 15....

 Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive defect belonging to the family of ciliopathies. Children born from consanguineous marriages are mostly affected. The primary manifestations of BBS are rod-cone dystrophy (90 to 93%), postaxial polydactyly (62-82%), obesity (73-91%), learning disabilities (62%), genital abnormalities (59-98%), and renal abnormalities both morphological and functional (53%). The visual prognosis for children with BBS is poor, with a mean age of legal blindness of 15 years. Significant weight gain begins within the first year and becomes a lifelong issue for most individuals. Most individuals have significant learning difficulties, but only a minority have severe impairment on IQ testing. Renal disease is a major cause of morbidity and mortality. Clinical findings establish the diagnosis of BBS. Multiple genes are known to be associated with BBS: BBS1, BBS2, ARL6 (BBS3), BBS4, BBS5, MKKS (BBS6), BBS7, TTC8 (BBS8), BBS9, BBS10, TRIM32 (BBS11), ...

 Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive defect belonging to the family of ciliopathies. Children born from consanguineous marriages are mostly affected. The primary manifestations of BBS are rod-cone dystrophy (90 to 93%), postaxial polydactyly (62-82%), obesity (73-91%), learning disabilities (62%), genital abnormalities (59-98%), and renal abnormalities both morphological and functional (53%). The visual prognosis for children with BBS is poor, with a mean age of legal blindness of 15 years. Significant weight gain begins within the first year and becomes a lifelong issue for most individuals. Most individuals have significant learning difficulties, but only a minority have severe impairment on IQ testing. Renal disease is a major cause of morbidity and mortality. Clinical findings establish the diagnosis of BBS. Multiple genes are known to be associated with BBS: BBS1, BBS2, ARL6 (BBS3), BBS4, BBS5, MKKS (BBS6), BBS7, TTC8 (BBS8), BBS9, BBS10, TRIM32 (BBS11), ...